Asarina Pharma AB (publ) Year-end 2019 Report released
Asarina Pharma AB (publ) (ASAP: FN Stockholm) today publishes its Q4 and Year-end report for 2019. CEO Peter Nordkild: “We have been very busy during an intensive last quarter of 2019 progressing Sepranolone in all three of our indications; PMDD, menstrual migraine and Tourette syndrome and raising SEK 48 million in a directed share issue.”
- Total operating expenses amounted to SEK 20.8 million, of which about 2/3 were clinical costs related to the Phase II studies in PMDD and menstrual migraine.
- The company conducted a directed share issue in October 2019, raising gross proceeds of SEK 47.5 million.
- On 31 December 2019, the company had a total cash position of SEK 130 million.
PREMENSTRUAL DYSPHORIC DISORDER
We enrolled the last patient in our Phase IIb study in our lead indication, Premenstrual Dysphoric Disorder (PMDD), in September, and administered last injection on 26 January. We are on track to publish topline results by the end of April.
MENSTRUAL MIGRAINE TRIAL
We included the first patient in our Phase IIa proof-of-concept study in August and first patients started their treatment cycles in January. We expect last dose to be administered before the end of 2020, and topline results released Q1 2021.
In October we raised SEK 48 million, mainly for conducting a Phase IIa proof-of-concept study in this large orphan indication. We aim to initiate the study at the National Danish Tourette Center at the University hospital in Herlev before the end of 2020.
AUTOINJECTOR – YPSOMATE FROM YPSOMED
In October, we signed an agreement with the Swiss company Ypsomed for a customized Ypsomate autoinjector for Sepranolone proprietary to Asarina Pharma. It will be used from our first phase III PMDD study onwards.
Read the Full report HERE.
For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
Jakob Dynnes Hansen, CFO, Asarina Pharma AB
Phone: +45 5132 3698
Erik Penser Bank AB
Phone: +46 8-463 83 00
About Asarina Pharma
We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAA Modulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women’s Health company.
The information above was provided by Asarina Pharma AB (publ) through the above contact person, for publication at 8.00 CET on 21 February 2020.